PPT-Switch to INSTI NNRTI Switch to DTG RPV

SWORD Study Switch to CAB LA RPV LA IM LATTE2 Study LATTE2 Study switch to cabotegravir LA rilpivirine LA IM Objective Primary HIV RNA lt 50 cmL at W32 of maintenance phase selection of dosing schedule for phase III studies confirmation of dose on W48 analysis safety. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . PROBE . Study. PROBE Study: switch to DRV/r + RPV . Design. Age ≥ 18 years. HIV+. No previous resistance to study drugs. HIV-1 RNA. < 50 c/ml ≥ 6 months. On stable (≥ 6 months) . PI/r + 2 NRTI (TDF/FTC or ABC/3TC). Switch to DTG + RPV. SWORD. . Study. Switch to CAB LA + RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA + rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus . 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study. Michael Aboud,. 1. Richard Kaplan,. Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles 1 Queen Mary University, London, United Kingdom; 2 EPIMED GmbH, Berlin, Germany; 3 Hospital Universitario Fundación Jiménez Díaz , Madrid, Spain; 4 Central Institute of Epidemiology, Moscow, Russian Federation; STARTMRK. GS-US-236-0102 . SINGLE. Walmsley. S. NEJM 2013;369:1807-18. Design. Objective. Non inferiority of DTG at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (1-sided significance level of 2.5%, lower margin of . Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). ARV . strategies. DOR > DRV/r 1st line. (DRIVE-FORWARD W96). DTG. monotherapy. Switch PI/r-DTG (NEAT22). Switch RPV+DTG . (SWORD). Test and . Treat. D/C/F/TAF . (DIAMOND). −10% noninferiority margin for individual studies.. 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. Dathan M. Byonanebye, Mark N. Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella . D’Arminio. Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric . 2. C Brinson,. 3. F Castelli,. 4. P-M Girard,. 5. LP Kahl,. 6. . E Blair,. 7. B Wynne,. 8. K Vandermeulen,. 9. M Aboud. 10. . SWORD 1 & 2: Switch to . DTG + RPV Maintains Virologic . Suppression Through 48 Weeks, a Phase III Study.